Sugi Predict

Sugi Predict / Compounds / SCHEMBL24680368

SCHEMBL24680368

SCHEMBL24680368

CC(C)c1cc(O)cc2ccc(F)c(F)c12

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ESR1 P03372 10/20 0.35
▸ ESR2 Q92731 10/20 0.35
▸ ADRA2A P08913 1/20 0.35
▸ ADRA2B P18089 1/20 0.35
▸ ADRA2C P18825 1/20 0.35
▸ EIF4A3 P38919 1/20 0.35
▸ GABRA1 P14867 4/20 0.33
▸ GABRB1 P18505 2/20 0.33
▸ RPS6KA3 P51812 1/20 0.33
▸ GABRB2 P47870 3/20 0.32
▸ LMNA P02545 2/20 0.32
▸ SLC6A2 P23975 2/20 0.32
▸ HTR2B P41595 2/20 0.32
▸ TRPA1 O75762 1/20 0.32
▸ CHRM1 P11229 1/20 0.32
▸ ADRA1A P35348 1/20 0.32
▸ CA1 P00915 2/20 0.31
▸ CA2 P00918 2/20 0.31
▸ CYP1A2 P05177 2/20 0.31
▸ FAAH O00519 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25791156 0.87 PDE2A (0.36) ESR1ESR2ADRA2AADRA2BADRA2C
SCHEMBL27052247 0.85 HDAC3 (0.35) ESR1ESR2EIF4A3GABRA1GABRB1
SCHEMBL27358439 0.85 ESR1 (0.34) ESR1ESR2ADRA2AADRA2BADRA2C
SCHEMBL24791858 0.85 LMNA (0.34) ESR1ESR2ADRA2AADRA2BADRA2C
SCHEMBL24176030 0.85 GABRA1 (0.40) ESR1ESR2ADRA2AADRA2BADRA2C
SCHEMBL25080955 0.84 ADRA2A (0.32) ESR1ESR2ADRA2AADRA2BADRA2C
SCHEMBL27052256 0.83 GABRA1 (0.35) ESR1ESR2EIF4A3GABRA1GABRB1
SCHEMBL25046942 0.83 GABRA1 (0.35) ESR1ESR2ADRA2AADRA2BADRA2C
SCHEMBL24630608 0.81 ESR1 (0.37) ESR1ESR2ADRA2AADRA2BADRA2C
SCHEMBL26707331 0.81 TDP1 (0.35) ESR1ESR2ADRA2AADRA2BADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240217972-A1 GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF TIGER BIOTHERAPEUTICS INC. 2024-07-04 — — US disclosed
US-20240217972-A1 GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF TIGER BIOTHERAPEUTICS INC. 2024-07-04 — — US disclosed
US-20240216516-A1 GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF TIGER BIOTHERAPEUTICS INC. 2024-07-04 — — US disclosed
US-20240216516-A1 GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF TIGER BIOTHERAPEUTICS INC. 2024-07-04 — — US disclosed
WO-2024050742-A1 BIFUNCTIONAL COMPOUNDS FOR DEGRADING KRAS G12D VIA UBIQUITIN PROTEASOME PATHWAY NIKANG THERAPEUTICS, INC. (US) 2024-03-14 — — WO disclosed
US-20240025918-A1 KRAS G12D Inhibitors JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2024-01-25 — — US disclosed
US-20240025918-A1 KRAS G12D Inhibitors JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2024-01-25 — — US disclosed
US-20230365595-A1 INHIBITORS OF KRAS(G12D) RANOK THERAPEUTICS (HANGZHOU) CO. LTD. (CN) 2023-11-16 — — US disclosed
WO-2023274324-A9 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR, INTERMEDIATE THEREOF, AND APPLICATION THEREOF 上海艾力斯医药科技股份有限公司 2023-10-26 — — WO disclosed
WO-2023173017-A1 KRAS INHIBITORS FOR TREATING DISEASE BLOSSOMHILL THERAPEUTICS, INC. (US) 2023-09-14 — — WO disclosed
WO-2023134465-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR, INTERMEDIATE THEREOF AND USE THEREOF 上海艾力斯医药科技股份有限公司 2023-07-20 — — WO disclosed
WO-2023114733-A1 KRAS MODULATORS AND USES THEREOF QUANTA THERAPEUTICS, INC. (US) 2023-06-22 — — WO disclosed
WO-2023103906-A1 KRAS G12D INHIBITOR AND USE IN MEDICINE 贝达药业股份有限公司 2023-06-15 — — WO disclosed
WO-2023020519-A1 1, 4-OXAZEPANE DERIVATIVES AND USES THEREOF JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2023-02-23 — — WO disclosed
WO-2023020518-A1 N-CYCLOPROPYLPYRIDO [4, 3-D] PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2023-02-23 — — WO disclosed
WO-2023018809-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2023-02-16 — — WO disclosed
WO-2023018812-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2023-02-16 — — WO disclosed
WO-2023274324-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR, INTERMEDIATE THEREOF, AND APPLICATION THEREOF 上海艾力斯医药科技股份有限公司 2023-01-05 — — WO disclosed
WO-2022261210-A1 KRAS MODULATORS AND USES THEREOF QUANTA THERAPEUTICS, INC. (US) 2022-12-15 — — WO disclosed
WO-2022188729-A1 FUSED RING DERIVATIVES USEFUL AS KRAS G12D INHIBITORS JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2022-09-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240216516-A1 GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF KRAS, VHL, HRAS ESR1 1673/4885ESR2 3118/4885ADRA2A 4738/4885
US-20240217972-A1 GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF KRAS, VHL, HRAS ESR1 2738/4885ESR2 3551/4885ADRA2A 4763/4885
US-20230365595-A1 INHIBITORS OF KRAS(G12D) KRAS, NRAS, HRAS ESR1 1455/4885ESR2 2446/4885ADRA2A 4704/4885
US-20240025918-A1 KRAS G12D Inhibitors KRAS, NRAS, HRAS ESR1 1518/4885ESR2 2178/4885ADRA2A 4613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.